BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that data from a phase I clinical trial evaluating every three week dosing of SGN-35 and a phase I clinical trial of lintuzumab (SGN-33) will be reported at the 14th Congress of the European Hematology Association (EHA) being held June 4-7, 2009 in Berlin, Germany. The abstracts are available from the EHA website at www.ehaweb.org.
